HRP20200961T1 - Test za hvatanje i detektiranje cirkulirajućih stanica multiplog mijeloma iz krvi - Google Patents
Test za hvatanje i detektiranje cirkulirajućih stanica multiplog mijeloma iz krvi Download PDFInfo
- Publication number
- HRP20200961T1 HRP20200961T1 HRP20200961TT HRP20200961T HRP20200961T1 HR P20200961 T1 HRP20200961 T1 HR P20200961T1 HR P20200961T T HRP20200961T T HR P20200961TT HR P20200961 T HRP20200961 T HR P20200961T HR P20200961 T1 HRP20200961 T1 HR P20200961T1
- Authority
- HR
- Croatia
- Prior art keywords
- sample
- blood
- cmmc
- patient
- additional marker
- Prior art date
Links
- 210000004369 blood Anatomy 0.000 title claims 7
- 239000008280 blood Substances 0.000 title claims 7
- 208000034578 Multiple myelomas Diseases 0.000 title claims 5
- 206010035226 Plasma cell myeloma Diseases 0.000 title claims 5
- 238000003556 assay Methods 0.000 title 1
- 238000000034 method Methods 0.000 claims 16
- 239000000523 sample Substances 0.000 claims 15
- 239000003550 marker Substances 0.000 claims 8
- RZBCCAZHJQZKLL-UHFFFAOYSA-N 5-methoxy-12-methyl-11h-indolo[2,3-a]carbazole-6-carbonitrile Chemical compound N1C2=C3N(C)C4=CC=C[CH]C4=C3C(OC)=C(C#N)C2=C2[C]1C=CC=C2 RZBCCAZHJQZKLL-UHFFFAOYSA-N 0.000 claims 7
- 239000003446 ligand Substances 0.000 claims 6
- 239000006249 magnetic particle Substances 0.000 claims 4
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical group C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 230000001225 therapeutic effect Effects 0.000 claims 3
- 230000002159 abnormal effect Effects 0.000 claims 2
- 210000004027 cell Anatomy 0.000 claims 2
- 210000003040 circulating cell Anatomy 0.000 claims 2
- 210000004180 plasmocyte Anatomy 0.000 claims 2
- 239000003153 chemical reaction reagent Substances 0.000 claims 1
- 230000007423 decrease Effects 0.000 claims 1
- 239000013610 patient sample Substances 0.000 claims 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B03—SEPARATION OF SOLID MATERIALS USING LIQUIDS OR USING PNEUMATIC TABLES OR JIGS; MAGNETIC OR ELECTROSTATIC SEPARATION OF SOLID MATERIALS FROM SOLID MATERIALS OR FLUIDS; SEPARATION BY HIGH-VOLTAGE ELECTRIC FIELDS
- B03C—MAGNETIC OR ELECTROSTATIC SEPARATION OF SOLID MATERIALS FROM SOLID MATERIALS OR FLUIDS; SEPARATION BY HIGH-VOLTAGE ELECTRIC FIELDS
- B03C1/00—Magnetic separation
- B03C1/005—Pretreatment specially adapted for magnetic separation
- B03C1/01—Pretreatment specially adapted for magnetic separation by addition of magnetic adjuvants
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B03—SEPARATION OF SOLID MATERIALS USING LIQUIDS OR USING PNEUMATIC TABLES OR JIGS; MAGNETIC OR ELECTROSTATIC SEPARATION OF SOLID MATERIALS FROM SOLID MATERIALS OR FLUIDS; SEPARATION BY HIGH-VOLTAGE ELECTRIC FIELDS
- B03C—MAGNETIC OR ELECTROSTATIC SEPARATION OF SOLID MATERIALS FROM SOLID MATERIALS OR FLUIDS; SEPARATION BY HIGH-VOLTAGE ELECTRIC FIELDS
- B03C1/00—Magnetic separation
- B03C1/02—Magnetic separation acting directly on the substance being separated
- B03C1/28—Magnetic plugs and dipsticks
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57426—Specifically defined cancers leukemia
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B03—SEPARATION OF SOLID MATERIALS USING LIQUIDS OR USING PNEUMATIC TABLES OR JIGS; MAGNETIC OR ELECTROSTATIC SEPARATION OF SOLID MATERIALS FROM SOLID MATERIALS OR FLUIDS; SEPARATION BY HIGH-VOLTAGE ELECTRIC FIELDS
- B03C—MAGNETIC OR ELECTROSTATIC SEPARATION OF SOLID MATERIALS FROM SOLID MATERIALS OR FLUIDS; SEPARATION BY HIGH-VOLTAGE ELECTRIC FIELDS
- B03C2201/00—Details of magnetic or electrostatic separation
- B03C2201/26—Details of magnetic or electrostatic separation for use in medical applications
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Cell Biology (AREA)
- Oncology (AREA)
- Food Science & Technology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Hospice & Palliative Care (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Claims (13)
1. Postupak hvatanja, izoliranja i analiziranja cirkulirajućih stanica multiplog mijeloma u uzorku krvi dobivenom iz ispitnog subjekta, koji obuhvaća
(a) kontaktiranje navedenog uzorka s koloidnim magnetnim česticama koje su konjugirane s prvim ligandom, koji je anti-CD138, i s drugim ligandom, koji je anti-CD38;
(b) podvrgavanje uzorka iz koraka (a) magnetnom polјu, da bi se proizvela odvojena frakcija cirkulirajućih stanica multiplog mijeloma vezanih za magnetne čestice;
(c) tretiranje uzorka iz koraka (b) s prvim dodatnim markerom; i
(d) analizu cirkulirajućih stanica multiplog mijeloma.
2. Postupak prema patentnom zahtjevu 1, pri čemu je uzorak volumena od oko 2 ml do oko 10 ml, od oko 3 ml do oko 7,5 ml ili od oko 4 ml.
3. Postupak prema patentnom zahtjevu 1, pri čemu su navedene koloidne magnetne čestice konjugirane s više od dva liganda, opcionalno gdje je jedan od liganada anti-CD56.
4. Postupak prema patentnom zahtjevu 1, pri čemu je navedeni prvi dodatni marker izabran iz grupe koja se sastoji od DAPI, anti-CD38, anti-CD19 i anti-CD45 anti-CD138, anti-CD56, anti-lambda, anti-kapa anti-CD200, anti-Ki67.
5. Postupak prema patentnom zahtjevu 1, koji dodatno obuhvaća kontaktiranje uzorka iz koraka (b) s drugim dodatnim markerom, opcionalno (i) gdje je drugi dodatni marker izabran iz grupe koja se sastoji od anti-CD19, anti-CD45 i DAPI boje.
6. Postupak prema patentnom zahtjevu 5, koji dodatno obuhvaća kontaktiranje uzorka iz koraka (b) s trećim dodatnim markerom, opcionalno gdje je treći dodatni marker izabran iz grupe koja se sastoji od anti-CD19, anti-CD45 i DAPI boje.
7. Postupak prema patentnom zahtjevu 6, koji dodatno obuhvaća kontaktiranje uzorka iz koraka (b) s četvrtim dodatnim markerom, opcionalno gdje je četvrti dodatni marker anti-CD45.
8. Postupak prema patentnom zahtjevu 1, koji dodatno obuhvaća kontaktiranje uzorka iz koraka (b) s četiri ili više dodatnih markera.
9. Postupak utvrđivanja da li je pacijent vjerojatni kandidat za terapijsku intervenciju kod oboljenja povezanih s abnormalnim plazma stanicama, koji obuhvaća
(a) obradu krvi navedenog pacijenta da bi se utvrdilo koliko je CMMC-a prisutno u uzorku, pri čemu obrada predstavlja postupak prema bilo kojem od patentnih zahtjeva 1-8; i
(b) određivanje, putem brojanja, da li je broj CMMC prisutan u navedenom uzorku jednak ili veći od ili jednak normalnom opsegu.
10. Postupak prema patentnom zahtjevu 9, pri čemu je normalan raspon CMMC u uzorku pacijenta manji od 7 CMMC u oko od 2 mL do 10 mL krvi.
11. Postupak prema patentnom zahtjevu 9, koji dodatno obuhvaća preporuku terapijske intervencije ukoliko je broj CMMC veći od 8 u oko od 2 mL do oko 10 mL krvi.
12. Postupak utvrđivanja da li se kod pacijenta koji je podvrgnut terapijskoj intervenciji smanjuje broj CMMC ili utvrđivanja da li pacijent koji je imao bolest abnormalnih plazma stanica i koji je uspješno liječen od takve bolesti, ostaje u remisiji; postupak koji obuhvaća
(a) obradu krvi navedenog pacijenta da bi se utvrdilo koliko je CMMC prisutno u uzorku u prvoj vremenskoj točki, pri čemu obrada predstavlja postupak prema bilo kojem od patentnih zahtjeva 1-8;
(b) određivanje, putem brojanja, da li je broj CMMC prisutan u navedenom uzorku jednak ili veći od ili jednak normalnom opsegu;
(c) obradu krvi navedenog pacijenta da bi se utvrdilo koliko je CMMC prisutno u uzorku u drugoj vremenskoj točki, pri čemu obrada predstavlja postupak prema bilo kojem od patentnih zahtjeva 1-8;
(d) određivanje, putem brojanja, da li je broj CMMC-a prisutan u navedenom uzorku jednak ili veći od ili jednak normalnom opsegu;
(e) uspoređivanje brojeva u koracima (b) i (d).
13. Reagens za hvatanje cirkulirajućih stanica multiplog mijeloma koji sadrži koloidne magnetne čestice i najmanje dva liganda, pri čemu najmanje dva liganda sadrže anti-CD138 i anti-CD38.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161510170P | 2011-07-21 | 2011-07-21 | |
EP12740854.0A EP2734307B1 (en) | 2011-07-21 | 2012-07-20 | Assay to capture and detect circulating multiple myeloma cells from blood |
PCT/US2012/047747 WO2013013222A1 (en) | 2011-07-21 | 2012-07-20 | Assay to capture and detect circulating multiple myeloma cells from blood |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20200961T1 true HRP20200961T1 (hr) | 2020-10-02 |
Family
ID=46584417
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20200961TT HRP20200961T1 (hr) | 2011-07-21 | 2020-06-17 | Test za hvatanje i detektiranje cirkulirajućih stanica multiplog mijeloma iz krvi |
Country Status (20)
Country | Link |
---|---|
US (1) | US9618515B2 (hr) |
EP (1) | EP2734307B1 (hr) |
JP (2) | JP6301250B2 (hr) |
CN (3) | CN108375676B (hr) |
BR (1) | BR112014001423B1 (hr) |
CA (1) | CA2842679C (hr) |
CY (1) | CY1123172T1 (hr) |
DK (1) | DK2734307T3 (hr) |
ES (1) | ES2799581T3 (hr) |
HK (1) | HK1259414A1 (hr) |
HR (1) | HRP20200961T1 (hr) |
HU (1) | HUE049527T2 (hr) |
LT (1) | LT2734307T (hr) |
MX (1) | MX351113B (hr) |
PL (1) | PL2734307T3 (hr) |
PT (1) | PT2734307T (hr) |
RS (1) | RS60783B1 (hr) |
SI (1) | SI2734307T1 (hr) |
TW (2) | TWI605122B (hr) |
WO (1) | WO2013013222A1 (hr) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL2972359T3 (pl) | 2013-03-15 | 2021-03-08 | Menarini Silicon Biosystems S.P.A. | Wzbogacanie krążących komórek nowotworowych poprzez deplecję białych krwinek |
EP3589952A4 (en) | 2017-02-28 | 2021-03-10 | Menarini Silicon Biosystems S.p.A. | IMPROVED KITS AND ASSAYS TO DETECT CIRCULATING MULTIPLE MYELOMA CELLS FROM BLOOD |
US11103351B2 (en) | 2017-04-05 | 2021-08-31 | Opus Medical Therapies, LLC | Transcatheter atrial sealing skirt and related method |
US11337685B2 (en) | 2017-04-05 | 2022-05-24 | Opus Medical Therapies, LLC | Transcatheter anchoring assembly for a mitral valve, a mitral valve, and related methods |
US10820992B2 (en) | 2017-04-05 | 2020-11-03 | Opus Medical Therapies, LLC | Transcatheter atrial sealing skirt, anchor, and tether and methods of implantation |
US11123187B2 (en) | 2017-04-05 | 2021-09-21 | Opus Medical Therapies, LLC | Transcatheter atrial anchors and methods of implantation |
BR112019020867B1 (pt) | 2017-04-05 | 2021-08-31 | Opus Medical Therapies, Llc. | Conjunto médico para implantar minimamente invasivamente uma válvula no coração |
CN109991410B (zh) * | 2017-12-29 | 2022-07-05 | 上海白泽医学检验所有限公司 | 一种含抗cd45单抗的组合物及其使用方法 |
CN109270262B (zh) * | 2018-10-08 | 2022-05-20 | 宁波美晶医疗技术有限公司 | 一种基于微流体技术的激光单细胞提取方法 |
CA3162885A1 (en) | 2020-01-22 | 2021-07-29 | Vivek RAJAGOPAL | Transcatheter anchor support, systems and methods of implantation |
JP2023544036A (ja) | 2020-10-01 | 2023-10-19 | オーパス メディカル セラピーズ、エルエルシー | 経カテーテルアンカー支持部および埋込の方法 |
CN112698037B (zh) * | 2021-03-25 | 2021-06-25 | 北京积水潭医院 | 一种检测多发性骨髓瘤治疗效果的抗体组合物及其试剂盒和应用 |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5597531A (en) | 1985-10-04 | 1997-01-28 | Immunivest Corporation | Resuspendable coated magnetic particles and stable magnetic particle suspensions |
US5698271A (en) | 1989-08-22 | 1997-12-16 | Immunivest Corporation | Methods for the manufacture of magnetically responsive particles |
US5646001A (en) * | 1991-03-25 | 1997-07-08 | Immunivest Corporation | Affinity-binding separation and release of one or more selected subset of biological entities from a mixed population thereof |
US5840502A (en) | 1994-08-31 | 1998-11-24 | Activated Cell Therapy, Inc. | Methods for enriching specific cell-types by density gradient centrifugation |
AU760315B2 (en) | 1998-01-16 | 2003-05-15 | Doppel Co., Ltd. | Non-slip artificial stone |
KR100399475B1 (ko) * | 1998-02-12 | 2003-09-29 | 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 | 순환 중인 암세포의 신속하고 효과적인 분리 방법 및 이를위한 제제 |
US6623982B1 (en) * | 1999-07-12 | 2003-09-23 | Immunivest Corporation | Increased separation efficiency via controlled aggregation of magnetic nanoparticles |
WO2001017687A2 (en) * | 1999-09-03 | 2001-03-15 | Miltenyi Biotec Gmbh | Methods of modification of selected cells in a magnetic cell separation column |
US7863012B2 (en) * | 2004-02-17 | 2011-01-04 | Veridex, Llc | Analysis of circulating tumor cells, fragments, and debris |
JP2005512557A (ja) * | 2001-11-07 | 2005-05-12 | ザ ボード オブ トラスティーズ オブ ザ ユニヴァーシティー オブ アーカンソー | 遺伝子発現プロファイリングに基づく多発性骨髄腫の診断、予後、および治療標的候補の同定 |
US7011794B2 (en) | 2002-11-25 | 2006-03-14 | Immunivest Corporation | Upon a cartridge for containing a specimen sample for optical analysis |
US7901950B2 (en) | 2005-08-12 | 2011-03-08 | Veridex, Llc | Method for assessing disease states by profile analysis of isolated circulating endothelial cells |
BRPI0712225A8 (pt) * | 2006-06-02 | 2019-01-22 | Pfizer Producs Inc | métodos para prever e monitorar a eficácia da terapia antagonista de igf-1r |
WO2008031064A1 (en) * | 2006-09-07 | 2008-03-13 | University Of South Florida | Hyd1 peptides as anti-cancer agents |
JP2010502210A (ja) * | 2006-09-07 | 2010-01-28 | ウニベルシダド・デ・サラマンカ | 遺伝子マーカーを使用する癌幹細胞の同定 |
AU2007302626B2 (en) * | 2006-09-28 | 2013-09-26 | The Macfarlane Burnet Institute For Medical Research And Public Health Limited | A method of diagnosis and kit therefor |
CN101878429B (zh) * | 2007-11-27 | 2015-05-20 | 维里德克斯有限责任公司 | 血液中循环黑素瘤细胞的自动化计数和表征 |
US20110269638A1 (en) * | 2011-04-29 | 2011-11-03 | Epstein Joshua | Genes associated with post relapse survival and uses thereof |
-
2012
- 2012-07-20 US US13/554,623 patent/US9618515B2/en active Active
- 2012-07-20 RS RS20200689A patent/RS60783B1/sr unknown
- 2012-07-20 JP JP2014521855A patent/JP6301250B2/ja active Active
- 2012-07-20 PT PT127408540T patent/PT2734307T/pt unknown
- 2012-07-20 DK DK12740854.0T patent/DK2734307T3/da active
- 2012-07-20 CA CA2842679A patent/CA2842679C/en active Active
- 2012-07-20 CN CN201711460248.6A patent/CN108375676B/zh active Active
- 2012-07-20 LT LTEP12740854.0T patent/LT2734307T/lt unknown
- 2012-07-20 SI SI201231791T patent/SI2734307T1/sl unknown
- 2012-07-20 BR BR112014001423-0A patent/BR112014001423B1/pt active IP Right Grant
- 2012-07-20 HU HUE12740854A patent/HUE049527T2/hu unknown
- 2012-07-20 CN CN202111649476.4A patent/CN114460286A/zh active Pending
- 2012-07-20 MX MX2014000804A patent/MX351113B/es active IP Right Grant
- 2012-07-20 CN CN201280046226.4A patent/CN103826750B/zh active Active
- 2012-07-20 PL PL12740854T patent/PL2734307T3/pl unknown
- 2012-07-20 WO PCT/US2012/047747 patent/WO2013013222A1/en active Application Filing
- 2012-07-20 EP EP12740854.0A patent/EP2734307B1/en active Active
- 2012-07-20 ES ES12740854T patent/ES2799581T3/es active Active
- 2012-07-23 TW TW101126473A patent/TWI605122B/zh active
- 2012-07-23 TW TW105127783A patent/TWI663399B/zh active
-
2018
- 2018-02-28 JP JP2018034448A patent/JP6821619B2/ja active Active
-
2019
- 2019-01-31 HK HK19101784.7A patent/HK1259414A1/zh unknown
-
2020
- 2020-06-12 CY CY20201100541T patent/CY1123172T1/el unknown
- 2020-06-17 HR HRP20200961TT patent/HRP20200961T1/hr unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20200961T1 (hr) | Test za hvatanje i detektiranje cirkulirajućih stanica multiplog mijeloma iz krvi | |
JP2018100978A5 (hr) | ||
Micheva et al. | Single-synapse analysis of a diverse synapse population: proteomic imaging methods and markers | |
Melamud et al. | Metabolomic analysis and visualization engine for LC− MS data | |
Lee et al. | Efficient isolation and accurate in situ analysis of circulating tumor cells using detachable beads and a high‐pore‐density filter | |
Nikolic et al. | Metabolomics in hypertension | |
Lakshmikanth et al. | Mass cytometry and topological data analysis reveal immune parameters associated with complications after allogeneic stem cell transplantation | |
Prieto et al. | Monitoring sepsis using electrical cell profiling | |
JP2012530246A5 (hr) | ||
Chen et al. | Spatially resolved transcriptomics reveals genes associated with the vulnerability of middle temporal gyrus in Alzheimer’s disease | |
Ball et al. | Physiologically based pharmacokinetic modelling of drug penetration across the blood–brain barrier—towards a mechanistic IVIVE-based approach | |
Lee et al. | Scaled, high fidelity electrophysiological, morphological, and transcriptomic cell characterization | |
Zhou et al. | Metabolism of glycerophospholipid, bile acid and retinol is correlated with the early outcomes of autoimmune hepatitis | |
Simonsen et al. | Lymphatic filariasis control in Tanzania: effect of six rounds of mass drug administration with ivermectin and albendazole on infection and transmission | |
US20120178094A1 (en) | Method for Categorizing Circulating Tumor Cells | |
BR112014029181B8 (pt) | Processo para identificar, diagnosticar ou fornecer um prognóstico | |
EP3452221B1 (en) | Microfluidic neutrophil assays and systems for disease detection | |
Zhou et al. | Phycosphere microbial succession patterns and assembly mechanisms in a marine dinoflagellate bloom | |
Manolopoulou et al. | Novel kidney dissociation protocol and image-based flow cytometry facilitate improved analysis of injured proximal tubules | |
Li et al. | Presynaptic endosomal cathepsin D regulates the biogenesis of GABAergic synaptic vesicles | |
Dhakshinamoorthy et al. | Metabolomics identifies the intersection of phosphoethanolamine with menaquinone-triggered apoptosis in an in vitro model of leukemia | |
Salem et al. | Myeloma minimal residual disease testing in the United States: Evidence of improved standardization | |
Ionov et al. | Zeta potential technique for analyzing semen quality | |
JP2018521302A5 (hr) | ||
Silva et al. | Cytokines and chemokines systemic levels are related to dialysis adequacy and creatinine clearance in patients with end-stage renal disease undergoing hemodialysis |